BioAgilytix opens new 360biolabs Sydney lab to expand Australian bioanalytical services

BioAgilytix has opened a purpose-designed 360biolabs laboratory in Sydney to support early-phase clinical research and keep samples moving from Australian studies into global drug development programs. The new site adds capacity in Macquarie Park and gives the company a permanent presence alongside its Melbourne and Brisbane operations.

Why it matters: - The new Sydney lab gives BioAgilytix a larger Australian base for time-sensitive bioanalytical work. - The facility is positioned to support early-phase clinical studies and later-stage global programs. - The expansion adds local capacity near clinical sites, hospitals and research institutions in New South Wales.

What happened: - BioAgilytix opened a new purpose-designed laboratory for 360biolabs in Sydney, Australia. - The facility is located in the Macquarie Park Innovation District. - The site strengthens 360biolabs’ permanent presence in New South Wales. - BioAgilytix now has 360biolabs laboratories in Sydney, Melbourne and Brisbane.

The details: - The Sydney laboratory is a BSL-2 facility built for time-sensitive clinical samples and complex early-phase studies. - The lab supports PBMC isolation and flow cytometry. - The facility includes dedicated sample reception and storage areas. - The site also has ultra-low-temperature freezer capacity, vapor-phase nitrogen cryostorage and continuous temperature monitoring. - The Sydney team brings assay development and validation expertise. - Shared procedures, instrumentation and quality systems are designed to support assay transfer from development through clinical sample analysis. - BioAgilytix says assays developed at 360biolabs can be transferred across its laboratories in Australia, Europe and the United States. - That network supports integrated PK, immunogenicity and biomarker analysis from first-in-human studies through later-stage global programs. - The Sydney facility has NATA accreditation to ISO/IEC 17025. - Across its Australian operations, 360biolabs also holds NATA accreditation for GLP and GCLP.

Between the lines: - Australia remains an attractive location for early-phase research because of streamlined regulation, faster study start-up, globally accepted data standards and an R&D tax incentive for eligible sponsors. - The Sydney opening also signals BioAgilytix’s push to keep bioanalytical workflows connected across regions rather than fragmented by geography. - A permanent presence in Sydney gives 360biolabs another foothold in New South Wales’ growing clinical research sector.

What's next: - BioAgilytix will use the Sydney lab to support sponsors as programs move from early development into global trials. - The company is likely to lean on the combined Australia-Europe-U.S. lab network for cross-site assay transfer and continuity. - 360biolabs is positioning the expansion as a base for continued growth in the region.

The bottom line: - BioAgilytix is turning 360biolabs into a more connected global bioanalytical platform, with Sydney adding local capacity and international continuity.